Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

NCT06868732 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

288

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: JSKN016
DRUG: Carboplatin
DRUG: Furmonertinib Mesylate
DRUG: Ivonescimab
DRUG: Docetaxel
DRUG: Tislelizumab
DRUG: Pembrolizumab

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd